Analysis – Page 508 – Goldea Capital

Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Written by Customer Service on April 23, 2026. Posted in Public Companies.

SAN FRANCISCO and VANCOUVER, British Columbia, April 23, 2026 (GLOBE NEWSWIRE) — Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that Jade’s Board of Directors granted an equity award to Edward R. Conner, M.D., effective as of April 22, 2026, in connection with his appointment as Chief Medical Officer. The Board of Directors granted Dr. Conner non-qualified stock options to purchase an aggregate of 500,000 shares of the Company’s common stock under the Jade Biosciences, Inc. Employment Inducement Stock Incentive Plan (the “Inducement Plan”). The option grant was granted as an inducement material to Dr. Conner entering into employment with Jade in accordance with Nasdaq Listing Rule 5635(c)(4). The...

AB Artea bankas Invitation to 3 months of 2026 Financial Results webinar

Written by Customer Service on April 23, 2026. Posted in Public Companies.

AB Artea bankas (ROE1L) invites shareholders, investors, analysts and other stakeholders to join its Investors Webinar on the Q1 2026 financial results and highlights. The webinar will take place on 28 April 2026 at 8:30 a.m. (EEST) and will be held online in English. The webinar will be hosted by Vytautas Sinius, CEO, Tomas Varenbergas, CFO and Tautvydas Mėdžius, Strategy Partner, who will discuss the bank’s financial results for Q1 2026, recent developments, and will take questions from participants. Participants are encouraged to submit questions in advance to investors@artea.lt. The Q1 2026 results will be announced in advance on 27 April after trading hours. How to join the webinar: To join the webinar, please register via following link https://artea.zoomtv.lt. After successful registration You will be provided with the webinar link....

Transcenta Therapeutics Presents New Data for its Novel LIV1-Targeting ADC TST013 Demonstrating Potent Anti-Tumor Activity in PDX Models of Prostate Cancer and ER Positive /HER2 Negative Breast Cancer

Written by Customer Service on April 23, 2026. Posted in Public Companies.

PRINCETON, N.J. and SUZHOU, China, April 23, 2026 (GLOBE NEWSWIRE) — Transcenta Therapeutics (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, today announced the presentation of preclinical data highlighting its proprietary LIV1-targeting antibody-drug conjugates (ADC) at the 2026 AACR Annual Meeting. The data demonstrate strong anti-tumor activity, differentiated payload-dependent efficacy, and favorable tolerability profiles, supporting further development in LIV1-positive solid tumors. LIV1 is a member of the zinc transporter family, with limited normal tissue expression, and is found to be overexpressed with high prevalence in breast (93%), prostate (72%) and lung (10%) cancers, making it an...

Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

Written by Customer Service on April 23, 2026. Posted in Public Companies.

Dosing initiates clinical evaluation of NPX-5, a GMP-compliant, nature-derived psilocybin candidate across an expanded Australian site network NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a clinical-stage biopharmaceutical company developing nature-derived psychedelic therapeutics, today announced that the first patient has been dosed in its Phase IIb clinical trial evaluating NPX-5 (25mg of nature-derived psilocybin) for the treatment of Adjustment Disorder in patients with cancer in a palliative care setting. The initiation of dosing represents the first active clinical evaluation of NPX-5 at scale and marks the Company’s transition into systematic human data generation across its Australian clinical network. NPX-5 is a GMP-compliant, nature-derived psilocybin...

Enterprise Deal Technology Procurement Has a New Standard

Written by Customer Service on April 23, 2026. Posted in Mergers And Acquisitions.

Deal technology procurement now requires sign-off from three groups: the deal team, the CISO, and the compliance officer, each with different criteria the vendor must meet Most deal technology vendors have added AI, but few can produce the governance documentation enterprise procurement now requires as a first-round question ISO 42001 for AI management has become an advantage for vendors For any cross-border deal, compliance coverage is a procurement baseline. Without verification, vendors can’t advanceMINNEAPOLIS, MN, April 23, 2026 (GLOBE NEWSWIRE) — Starting in April 2026, buying deal technology now involves more than just the deal team. The Chief Information Security Officer (CISO) has to approve the platform’s security, the compliance officer must confirm it meets legal and regulatory requirements, and the deal team has...

Descartes Acquires Idelic

Written by Customer Service on April 23, 2026. Posted in Mergers And Acquisitions.

Adds Critical Data to Global Logistics Network and Advances AI-Powered Fleet Safety and Performance Management Capabilities WATERLOO, Ontario and ATLANTA, April 23, 2026 (GLOBE NEWSWIRE) — Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that it has acquired Idelic, a leading provider of AI-powered driver safety and performance management solutions. Idelic’s safety intelligence platform unifies day-to-day safety management activities such as training, monitoring, reporting and coaching into a single solution. With an AI analytics workflow designed to measurably impact driver behavior, fleets can proactively identify and reduce driving risk by leveraging the platform’s unique dataset of more than 40 billion miles of telemetry and over 400,000 accident...

B2Gold Completes the Sale of its 70% Interest in Fingold

Written by Customer Service on April 23, 2026. Posted in Mergers And Acquisitions.

VANCOUVER, British Columbia, April 23, 2026 (GLOBE NEWSWIRE) — B2Gold Corp. (TSX: BTO, NYSE AMERICAN: BTG, NSX: B2G) (“B2Gold” or the “Company”) is pleased to announce that, further to its announcement on April 20, 2026, it has completed the sale of its 70% interest in Fingold Ventures Ltd. (“Fingold”) to Agnico Eagle Mines Limited (“Agnico Eagle”) (the “Transaction”). As per the terms of the Transaction, B2Gold received cash proceeds of US$325 million. B2Gold celebrates the completion of the Transaction and looks forward to collaborating with Agnico Eagle under the Nunavut Collaboration Agreement to share knowledge and operational best practices in Nunavut, Canada, as previously announced on April 20, 2026. About B2Gold Corp. B2Gold is a responsible international gold producer headquartered in Vancouver, Canada. Founded in 2007,...

Pool Corporation Reports First Quarter Results and Confirms Annual Earnings Guidance Range

Written by Customer Service on April 23, 2026. Posted in Earnings Releases And Operating Results.

Q1 2026 Highlights:Net sales increased 6%, driven by strong maintenance product sales and improvement in discretionary categories Gross margin of 29.0%, down 20 bps year-over-year, driven by increased early buy activity and seasonal mix in the first quarter Operating income increased 7% to $82.6 million; operating margin expanded 10 bps to 7.3% Diluted EPS of $1.45, an increase of 2%, or an increase of 8% without ASU 2016-09 tax benefits Confirms annual earnings guidance range of $10.87 – $11.17 per diluted share, including the Q1 2026 ASU 2016-09 tax benefit of $0.02COVINGTON, La., April 23, 2026 (GLOBE NEWSWIRE) — Pool Corporation (Nasdaq: POOL) today reported results for the first quarter of 2026. “We are off to a solid start in 2026, with net sales up 6% and operating income growing 7% year-over-year. Maintenance...

American Airlines Reports First-Quarter 2026 Financial Results

Written by Customer Service on April 23, 2026. Posted in Earnings Releases And Operating Results.

FORT WORTH, Texas, April 23, 2026 (GLOBE NEWSWIRE) — American Airlines Group Inc. (NASDAQ: AAL) today reported its first-quarter 2026 financial results, including:Record first-quarter revenue of $13.9 billion First-quarter GAAP net loss of $382 million, or ($0.58) per diluted share Excluding net special items1, first-quarter net loss of $267 million, or ($0.40) per diluted share Ended the quarter with total debt2 of $34.7 billion, the company’s lowest total debt level since mid-20152 Second-quarter adjusted EPS3 expected to be between ($0.20) and $0.20. Based on the forward fuel curve and the current revenue outlook, the midpoint of the full-year guidance is expected to be approximately flat to 2025, despite a greater than $4 billion increase in expense related to higher prices for jet fuel“American delivered record revenue...

ConnectOne Bancorp, Inc. Reports First Quarter 2026 Results

Written by Customer Service on April 23, 2026. Posted in Earnings Releases And Operating Results.

NET INTEREST MARGIN WIDENS BY 12 BASIS POINTS; TREND CONFIRMED10% ANNUALIZED LOAN GROWTHOPERATING PERFORMANCE ACCELERATESTANGIBLE BOOK VALUE PER SHARE INCREASES8.3% INCREASE IN COMMON DIVIDEND PER SHARE DECLARED ENGLEWOOD CLIFFS, N.J., April 23, 2026 (GLOBE NEWSWIRE) — ConnectOne Bancorp, Inc. (Nasdaq: CNOB) (the “Company” or “ConnectOne”), parent company of ConnectOne Bank (the “Bank”), today reported net income available to common stockholders of $36.3 million for the first quarter of 2026 compared with $38.0 million for the fourth quarter of 2025 and $18.7 million for the first quarter of 2025. Diluted earnings per share were $0.72 for the first quarter of 2026 compared with $0.75 for the fourth quarter of 2025 and $0.49 for the first quarter of 2025. Return on average assets was 1.10%, 1.12% and 0.84% for the three months ended...

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals